GSK’s ViiV Healthcare and its bimonthly pre-exposure prophylaxis (PrEP) medicine Apretude had to make room for another ...

In separate announcements Wednesday, a pair of agencies shared business updates both aimed at leveling up their respective ...

With sales of potential blockbuster Lokelma scaling up, AstraZeneca is bolstering its production of the hyperkalemia ...

Codis, born from the fusion of U.S.-based Particle Dynamics and a U.K. | In addition to substantial spray drying capacity, ...

Brexafemme (ibrexafungerp) partners GSK and Scynexis have worked out their quarrel related to a clinical trial that was previously put on hold, leaving Scynexis with a $22 million payout. | Through ...